Literature DB >> 24068011

Hepatitis C virus genotype 2 may not be detected by the Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 1.0.

Tsunamasa Watanabe1, Takako Inoue, Yasushi Tanoue, Hisato Maekawa, Susumu Hamada-Tsutsumi, Shinsho Yoshiba, Yasuhito Tanaka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24068011      PMCID： PMC3838077          DOI： 10.1128/JCM.02102-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  4 in total

1.  Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity.

Authors:  Johannes Vermehren; Giuseppe Colucci; Peter Gohl; Nabila Hamdi; Ahmed Ihab Abdelaziz; Ursula Karey; Diana Thamke; Heike Zitzer; Stefan Zeuzem; Christoph Sarrazin
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

2.  The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples.

Authors:  Stéphane Chevaliez; Magali Bouvier-Alias; Laurent Castéra; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

3.  The Cobas AmpliPrep/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA.

Authors:  Stéphane Chevaliez; Magali Bouvier-Alias; Christophe Rodriguez; Alexandre Soulier; Jean-Dominique Poveda; Jean-Michel Pawlotsky
Journal:  J Clin Microbiol       Date:  2013-01-16       Impact factor: 5.948

4.  Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method.

Authors:  Stéphane Chevaliez; Magali Bouvier-Alias; Rozenn Brillet; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425
  4 in total
  1 in total

1.  Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.

Authors:  Takako Inoue; Su Su Hmwe; Noritomo Shimada; Keizo Kato; Tatsuya Ide; Takuji Torimura; Takashi Kumada; Hidenori Toyoda; Akihito Tsubota; Koichi Takaguchi; Takaji Wakita; Yasuhito Tanaka
Journal:  PLoS One       Date:  2017-01-24       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.